HRP20100120T1 - Formulacije s valsartanom - Google Patents
Formulacije s valsartanom Download PDFInfo
- Publication number
- HRP20100120T1 HRP20100120T1 HR20100120T HRP20100120T HRP20100120T1 HR P20100120 T1 HRP20100120 T1 HR P20100120T1 HR 20100120 T HR20100120 T HR 20100120T HR P20100120 T HRP20100120 T HR P20100120T HR P20100120 T1 HRP20100120 T1 HR P20100120T1
- Authority
- HR
- Croatia
- Prior art keywords
- valsartan
- tablet
- microcrystalline cellulose
- pregelatinized starch
- magnesium stearate
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title claims abstract 6
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title claims abstract 6
- 229960004699 valsartan Drugs 0.000 title claims abstract 6
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 3
- 229920000881 Modified starch Polymers 0.000 claims abstract 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 3
- 239000013543 active substance Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 239000008119 colloidal silica Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Farmaceutska formulacija, naznačena time što je u obliku tablete koja sadrži- 20 do 34 % (težinski) valsartana kao aktivnog sredstva, - mikrokristalnu celulozu i preželatinirani škrob, u težinskom odnosu između 1:1 i 5:1, - koloidni silicijev dioksid, - magnezijev stearat, gdje se navedenu tabletu može načiniti izravnom kompresijom sastojaka pod tlakom od 90 N do 270 N. Patent sadrži još 2 patentna zahtjeva.
Claims (3)
1. Farmaceutska formulacija, naznačena time što je u obliku tablete koja sadrži
• 20 do 34 % (težinski) valsartana kao aktivnog sredstva,
• mikrokristalnu celulozu i preželatinirani škrob, u težinskom odnosu između 1:1 i 5:1,
• koloidni silicijev dioksid,
• magnezijev stearat,
gdje se navedenu tabletu može načiniti izravnom kompresijom sastojaka pod tlakom od 90 N do 270 N.
2. Tableta u skladu s patentnim zahtjevom 1, naznačena time što valsartan dolazi u količini između 80 i 320 mg valsartana.
3. Tableta u skladu s patentnim zahtjevom 1, naznačena time što sadrži:
20 do 34 % valsartana
40 do 60 % mikrokristalne celuloze
8 do 40 % preželatiniranog škroba
0,5 do 1,5 % koloidnog silicijevog dioksida
1,5 do 4,0 % magnezijavog stearata.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2007/03568A TR200703568A1 (tr) | 2007-05-24 | 2007-05-24 | Valsartan formülasyonları |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100120T1 true HRP20100120T1 (hr) | 2010-04-30 |
Family
ID=38982518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100120T HRP20100120T1 (hr) | 2007-05-24 | 2010-03-04 | Formulacije s valsartanom |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080293789A1 (hr) |
| EP (1) | EP1994926B9 (hr) |
| AT (1) | ATE451097T1 (hr) |
| CY (1) | CY1109865T1 (hr) |
| DE (1) | DE602008000367D1 (hr) |
| DK (1) | DK1994926T3 (hr) |
| ES (1) | ES2337848T3 (hr) |
| HR (1) | HRP20100120T1 (hr) |
| PL (1) | PL1994926T3 (hr) |
| PT (1) | PT1994926E (hr) |
| SI (1) | SI1994926T1 (hr) |
| TR (1) | TR200703568A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2405899A2 (en) * | 2009-03-11 | 2012-01-18 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Valsartan formulations |
| TR201005419A2 (tr) * | 2010-07-05 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Valsartan içeren farmasötik bileşim. |
| EP2990029A1 (en) * | 2014-08-29 | 2016-03-02 | Sandoz Ag | Pharmaceutical compositions comprising Canagliflozin |
| CN105769788A (zh) * | 2016-03-11 | 2016-07-20 | 江苏中邦制药有限公司 | 一种缬沙坦片剂及制备方法 |
| CN105816419A (zh) * | 2016-05-26 | 2016-08-03 | 陈欣怡 | 一种包含缬沙坦的药物组合物 |
| CN112807286A (zh) * | 2021-01-20 | 2021-05-18 | 海南皇隆制药股份有限公司 | 一种缬沙坦分散片制备方法和缬沙坦分散片 |
| CN112826806A (zh) * | 2021-01-20 | 2021-05-25 | 海南皇隆制药股份有限公司 | 一种缬沙坦片制备方法和缬沙坦片 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0511767A1 (en) | 1991-04-29 | 1992-11-04 | Merck & Co. Inc. | Tablets containing compound DUP753 |
| DE4408497A1 (de) | 1994-03-14 | 1995-09-21 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JPH09510225A (ja) | 1994-03-17 | 1997-10-14 | チバ−ガイギー アクチェンゲゼルシャフト | バルサルタンを用いる糖尿病性ネフロパシーの治療 |
| TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| CZ293257B6 (cs) | 1998-12-23 | 2004-03-17 | Novartis Ag | Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě |
| US20020132839A1 (en) * | 2000-06-22 | 2002-09-19 | Ganter Sabina Maria | Tablet formulations comprising valsartan |
| US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| PL382044A1 (pl) | 2003-11-03 | 2007-08-06 | Zentiva, A.S. | Preparat zawierający walsartan |
| SI2033629T1 (sl) * | 2004-12-24 | 2013-01-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Trden farmacevtski sestavek, ki obsega valsartan |
| CA2609026A1 (en) * | 2005-05-18 | 2007-03-08 | Combino Pharm, S.L. | Formulations containing losartan and/or its salts |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| WO2007049291A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Novel solid dosage forms of valsartan and rochlorothiazide |
| JP2009513622A (ja) * | 2005-10-27 | 2009-04-02 | ルピン・リミテッド | ロサルタンの医薬製剤 |
| WO2007052307A2 (en) * | 2005-10-31 | 2007-05-10 | Lupin Limited | Stable solid oral dosage forms of valsartan |
-
2007
- 2007-05-24 TR TR2007/03568A patent/TR200703568A1/xx unknown
-
2008
- 2008-05-23 PT PT08104077T patent/PT1994926E/pt unknown
- 2008-05-23 ES ES08104077T patent/ES2337848T3/es active Active
- 2008-05-23 US US12/126,353 patent/US20080293789A1/en not_active Abandoned
- 2008-05-23 PL PL08104077T patent/PL1994926T3/pl unknown
- 2008-05-23 DK DK08104077.6T patent/DK1994926T3/da active
- 2008-05-23 SI SI200830014T patent/SI1994926T1/sl unknown
- 2008-05-23 DE DE602008000367T patent/DE602008000367D1/de active Active
- 2008-05-23 AT AT08104077T patent/ATE451097T1/de active
- 2008-05-23 EP EP08104077A patent/EP1994926B9/en active Active
-
2010
- 2010-03-01 CY CY20101100204T patent/CY1109865T1/el unknown
- 2010-03-04 HR HR20100120T patent/HRP20100120T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2337848T3 (es) | 2010-04-29 |
| ATE451097T1 (de) | 2009-12-15 |
| CY1109865T1 (el) | 2014-09-10 |
| SI1994926T1 (sl) | 2010-04-30 |
| EP1994926A1 (en) | 2008-11-26 |
| DE602008000367D1 (de) | 2010-01-21 |
| EP1994926B9 (en) | 2010-05-19 |
| US20080293789A1 (en) | 2008-11-27 |
| PL1994926T3 (pl) | 2010-05-31 |
| EP1994926B1 (en) | 2009-12-09 |
| PT1994926E (pt) | 2010-03-16 |
| TR200703568A1 (tr) | 2008-07-21 |
| DK1994926T3 (da) | 2010-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100120T1 (hr) | Formulacije s valsartanom | |
| JP2010047612A5 (hr) | ||
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| MX2010007609A (es) | Formulacion de capsula. | |
| UA105766C2 (uk) | Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин | |
| RS54244B1 (en) | NALBUFINE BASED FORMULATIONS AND THEIR USE | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| NO20062082L (no) | Pellets inneholdende venlafaksinhydroklorid | |
| NO20084826L (no) | Ny administrasjonsform av racecadotril | |
| NZ600472A (en) | Anti-HIV tablet formulations comprising darunavir | |
| HRP20110162A8 (hr) | Spojevi koji sadrže amlodipin i bisoprolol | |
| TW200518785A (en) | Pharmaceutical formulation | |
| WO2005115346A3 (en) | Pharmaceutical composition containing risperidone | |
| JP2009091362A5 (hr) | ||
| WO2009008004A3 (en) | Sustained release formulations of divalproex sodium | |
| RS53086B (en) | OLMESARTAN PHARMACEUTICAL COMPOSITIONS | |
| UA107369C2 (en) | Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process | |
| RS54304A (en) | Amlodipine bezylate tabletes with improved stability | |
| WO2010103539A3 (en) | Sustained release oral formulation of vinpocetine | |
| MX2021015776A (es) | Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos. | |
| NZ709219A (en) | Gel compositions | |
| HUP0301537A2 (hu) | Deramcyclane-fumarátot tartalmazó tabletták és eljárás előállításukra | |
| WO2011149206A3 (en) | Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same | |
| WO2010104485A3 (en) | Valsartan formulations |